Profile data is unavailable for this security.
About the company
Shanghai Haohai Biological Technology Co., Ltd. is a China-based company principally engaged in biological technology-related businesses. The businesses of the Company include the manufacture and sales of biological and medical hyaluronate, the research and development of biological engineering and pharmaceutical products and the provision of related services. Its products include orthopedics products, medical aesthetics and wound care products, ophthalmology products and anti-adhesion and hemostasis products, among others. Orthopedics products include sodium hyaluronate injection, medical chitosan and medical sodium hyaluronate gel. Medical aesthetics and wound care products include recombinant human epidermal growth factor (rhEGF), among others. Ophthalmology products include ophthalmic viscoelastic devices and lubricant eye drops. Anti-adhesion and hemostasis products include medical collagen sponges, among others. The Company mainly operates businesses in Mainland China.
- Revenue in HKD (TTM)2.93bn
- Net income in HKD479.85m
- Incorporated2007
- Employees2.18k
- LocationShanghai Haohai Biological Technology Co Ltd4F, No 2 Building, Alley 139Anshun Road, Changning DistrictSHANGHAI 200336ChinaCHN
- Phone+86 2 152293555
- Fax+86 2 152293558
- Websitehttps://www.3healthcare.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fukuda Denshi Co Ltd | 6.91bn | 830.27m | 13.98bn | 3.44k | 13.08 | 1.24 | 14.28 | 2.02 | 565.94 | 565.94 | 4,709.89 | 5,965.54 | 0.6646 | 3.94 | 4.09 | 40,109,210.00 | 7.98 | 8.07 | 9.34 | 10.17 | 51.57 | 47.83 | 12.01 | 11.13 | 3.59 | -- | 0.0104 | 29.09 | 4.21 | 1.58 | 8.19 | 14.31 | 11.00 | 15.85 |
| Shanghai Runda Medical Technology Co Ltd | 9.08bn | 43.36m | 14.19bn | 3.32k | 326.80 | 3.07 | -- | 1.56 | 0.0673 | 0.0673 | 13.61 | 7.17 | 0.5831 | 4.19 | 1.49 | 2,543,990.00 | 1.18 | 4.78 | 3.13 | 12.86 | 25.94 | 27.13 | 2.03 | 6.36 | 1.01 | 3.04 | 0.5609 | 12.43 | -12.84 | 8.93 | -34.58 | 0.8514 | 3.88 | 1.03 |
| Shanghai MicroPort Edvcl MdTch Grp CoLtd | 1.37bn | 707.85m | 14.66bn | 908.00 | 20.30 | 3.50 | -- | 10.73 | 5.44 | 5.44 | 10.59 | 31.54 | 0.371 | 1.33 | 6.51 | 1,396,816.00 | 19.00 | 17.68 | 21.55 | 19.43 | 74.51 | 76.60 | 51.21 | 42.25 | 5.49 | -- | 0.0067 | 44.46 | 32.43 | 38.72 | 37.98 | 40.28 | 50.18 | -- |
| Sansure Biotech Inc | 1.52bn | 279.36m | 14.78bn | 2.01k | 52.67 | 1.87 | -- | 9.76 | 0.4475 | 0.4475 | 2.44 | 12.62 | 0.1667 | 0.878 | 2.03 | 701,473.70 | 2.52 | 26.74 | 2.79 | 30.97 | 76.43 | 67.47 | 15.12 | 42.01 | 7.45 | -- | 0.0583 | 22.40 | -84.39 | 27.12 | -81.22 | 121.89 | 64.08 | -- |
| Micro-Tech Nanjing Co Ltd | 2.88bn | 592.79m | 15.70bn | 2.40k | 26.40 | 3.91 | -- | 5.44 | 2.94 | 2.94 | 14.30 | 19.86 | 0.6118 | 1.65 | 6.80 | 1,114,222.00 | 12.87 | 10.74 | 15.26 | 12.82 | 66.04 | 63.04 | 21.04 | 19.37 | 3.99 | -- | 0.0183 | 35.43 | 21.78 | 21.20 | 46.99 | 20.32 | 39.33 | -- |
| Top Glove Corporation Bhd | 4.40bn | -108.12m | 15.80bn | 11.00k | -- | 1.52 | 33.52 | 3.59 | -0.0077 | -0.0077 | 0.314 | 0.7227 | 0.3598 | -- | 9.09 | -- | -0.2583 | 22.49 | -0.2995 | 27.85 | -- | -- | -0.7179 | 26.49 | 1.57 | -- | 0.0676 | -- | 11.46 | -12.12 | 93.32 | -- | -24.91 | -- |
| Shanghai Haohai Biological Technology | 2.93bn | 479.85m | 16.01bn | 2.18k | 12.53 | 1.16 | 24.17 | 5.46 | 2.42 | 2.42 | 14.53 | 26.18 | 0.3761 | 1.57 | 7.56 | 1,358,716.00 | 5.81 | 4.84 | 6.86 | 5.50 | 70.07 | 72.09 | 15.45 | 16.50 | 3.98 | -- | 0.0655 | 36.86 | 25.27 | 11.26 | 130.58 | 0.0762 | 11.96 | 14.22 |
| QuantumPharm Inc | 211.96m | -2.73bn | 16.59bn | 760.00 | -- | 3.74 | -- | 78.27 | -1.07 | -1.07 | 0.1025 | 1.30 | -- | -- | -- | 270,701.90 | -- | -- | -- | -- | -- | -- | -1,280.46 | -- | -- | -- | 0.038 | -- | 30.80 | -- | -33.08 | -- | -- | -- |
| Holder | Shares | % Held |
|---|---|---|
| Prudence Investment Management (Hong Kong) Ltd.as of 31 Dec 2023 | 2.76m | 6.74% |
| GF Fund Management Co., Ltd.as of 13 Nov 2023 | 1.95m | 4.76% |
| Fullgoal Fund Management Co., Ltd.as of 30 Jun 2024 | 1.93m | 4.72% |
| The Vanguard Group, Inc.as of 02 Oct 2024 | 1.55m | 3.78% |
| Dimensional Fund Advisors LPas of 03 Oct 2024 | 481.84k | 1.18% |
| China Southern Asset Management Co., Ltd.as of 30 Jun 2024 | 255.22k | 0.62% |
| SSgA Funds Management, Inc.as of 03 Oct 2024 | 66.68k | 0.16% |
| BlackRock Advisors (UK) Ltd.as of 03 Oct 2024 | 35.76k | 0.09% |
| BlackRock Fund Advisorsas of 03 Oct 2024 | 30.56k | 0.08% |
| Vanguard Fiduciary Trust Co.as of 31 Aug 2024 | 30.44k | 0.07% |
